The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 04, 2024

Filed:

Nov. 13, 2018
Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventors:

Luke Lairson, San Diego, CA (US);

Brittney Beyer, San Diego, CA (US);

Mingliang Fang, Singapore, SG;

Gary Siuzdak, Cardiff, CA (US);

Assignee:

The Scripps Research Institute, La Jolla, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); A61K 31/5415 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07C 303/02 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); A61P 25/00 (2018.01); C07C 303/02 (2013.01); C07K 16/286 (2013.01);
Abstract

This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.


Find Patent Forward Citations

Loading…